Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
Diphenhydramine vs ALFENTA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inverse agonist at histamine H1 receptors, blocking histamine-mediated effects in blood vessels, respiratory smooth muscle, and GI tract; also anticholinergic by blocking muscarinic receptors and sedative via central H1 receptor antagonism.
μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.
Allergic rhinitis,Urticaria,Pruritus,Insomnia (OTC sleep aid),Motion sickness,Parkinsonism (off-label for extrapyramidal symptoms)
Induction and maintenance of anesthesia,Analgesic supplement during surgical procedures,Intravenous use for monitored anesthesia care (MAC)
25-50 mg orally or intramuscularly every 4-6 hours; maximum 300 mg/day. Intravenous administration: 10-50 mg slow IV push (max 25 mg/min).
Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.
Terminal elimination half-life 4-8 hours in adults; prolonged in hepatic impairment (up to 20 hours) and elderly.
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours); prolonged in hepatic impairment.
Primarily hepatic via CYP2D6, with minor contributions from CYP1A2, CYP2C9, and CYP2C19; undergoes N-demethylation and N-oxidation; first-pass metabolism is extensive.
Hepatic via CYP3A4 to inactive metabolites; major metabolite is desmethylalfentanil (inactive).
Primarily renal (90-95% as metabolites, <5% unchanged). Minor biliary/fecal elimination (<5%).
Primarily renal (urinary) elimination as metabolites; approximately 80% recovered in urine, 20% in feces.
98-99% bound, primarily to albumin.
Approximately 92% bound, primarily to alpha-1 acid glycoprotein and albumin.
Vd 3-5 L/kg (wide distribution, high tissue binding).
0.5–1.0 L/kg; reflects moderate tissue distribution; higher Vd in neonates and elderly.
Oral: 50-70% (first-pass metabolism). IM: 100% (assumed). IV: 100%.
Intravenous: 100%; intramuscular: approximately 90%; intrathecal: approximately 10% (due to systemic absorption following spinal administration).
No specific dose adjustment for GFR. Use with caution in severe renal impairment (Cr Cl <10 m L/min) due to potential accumulation; consider reducing dose or extending interval.
No specific dose adjustment is recommended for renal impairment; however, alfentanil is primarily metabolized in the liver and its pharmacokinetics are not significantly altered in renal failure.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: use with caution, consider 25% of usual dose or avoid.
In hepatic impairment (Child-Pugh class A, B, C): Reduce dose by 50% and titrate carefully due to prolonged elimination half-life. Consider lower initial doses and extended dosing intervals.
Children 2-5 years: 6.25 mg orally every 4-6 hours (max 37.5 mg/day). Children 6-11 years: 12.5-25 mg orally every 4-6 hours (max 150 mg/day). Children ≥12 years: 25-50 mg orally every 4-6 hours (max 300 mg/day).
Children (1-12 years): Induction of anesthesia: 10-20 mcg/kg IV; maintenance: 5-10 mcg/kg IV or infusion 0.5-1 mcg/kg/min. For neonates and infants: Dose individualization required; titrate to effect.
Elderly patients (>65 years): initially 25 mg orally at bedtime, increase if needed; maximum 50 mg/day. Avoid as first-line antihistamine due to anticholinergic adverse effects (confusion, falls).
Elderly patients (>65 years): Reduce initial dose by 30-50% and administer slowly. Due to decreased clearance and increased sensitivity, lower infusion rates (e.g., 0.3-0.5 mcg/kg/min) may be needed.
Not recommended for use in neonates or premature infants due to potential association with sudden infant death syndrome (SIDS) and paradoxical CNS excitation.
Risk of respiratory depression, particularly in elderly or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Causes significant sedation, impairing ability to drive or operate machinery; anticholinergic effects may exacerbate narrow-angle glaucoma, urinary retention, hyperthyroidism, hypertension, and prostatic hypertrophy; avoid concurrent use with alcohol or other CNS depressants.
Respiratory depression; abuse potential; hypotension; bradycardia; muscle rigidity; serotonin syndrome with concurrent serotonergic drugs; adrenal insufficiency; risk of withdrawal with prolonged use.
Hypersensitivity to diphenhydramine or any antihistamine; acute asthma attack; concurrent MAOI therapy; breastfeeding (large doses may decrease milk production and cause infant sedation); narrow-angle glaucoma (absolute); urinary retention (absolute).
Hypersensitivity to alfentanil or any component; significant respiratory insufficiency; severe asthma; paralytic ileus; concurrent use of MAOIs (or within 14 days); acute or postoperative pain management in children (except for procedural sedation).
No significant food interactions. Grapefruit juice may theoretically inhibit CYP2D6 metabolism, but clinical relevance is minimal. Avoid alcohol due to additive CNS depression.
No known interactions with food. However, grapefruit juice may increase alfentanil serum concentrations due to CYP3A4 inhibition; avoid concurrent consumption.
First trimester: No increased risk of major congenital anomalies based on large cohort studies, though a weak association with oral clefts has been reported (RR ~1.3-1.5). Second trimester: No known risk. Third trimester: Near term, high doses may cause oxytocin-like effects; once-daily antihistamine effect with minimal fetal risk. Avoid use during late third trimester due to potential for uterine hyperstimulation.
Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effects were observed at clinically relevant doses; however, high doses caused embryotoxicity and increased fetal mortality. Trimester-specific risks: First trimester - potential for minor malformations based on limited human data; second trimester - possible risk if used chronically; third trimester - prolonged use may lead to neonatal respiratory depression, withdrawal syndrome, or opioid dependence. Use only if benefits outweigh risks.
Breastfeeding safety: Compatible, but caution advised due to potential for sedation and irritability in the infant. M/P ratio: Not clinically established; oral bioavailability is low but infant exposure is minimal at typical maternal doses. Avoid use in nursing mothers if alternative antihistamines with better safety profiles are available.
Alfentanil is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.3. Estimated infant dose is <1% of maternal weight-adjusted dose, which is considered clinically insignificant. However, due to potential for neonatal opioid effects, caution is advised; monitor infant for drowsiness, respiratory depression, and feeding difficulties. Consider alternative analgesics with established safety profiles, such as acetaminophen or ibuprofen, for lactation.
No specific dosing adjustments recommended based on pregnancy-induced pharmacokinetic changes. However, due to increased volume of distribution and altered hepatic metabolism in pregnancy, some clinicians may use lower starting doses for efficacy. Monitor for excessive sedation and adjust accordingly.
Pregnancy can alter pharmacokinetics of alfentanil. Increased plasma volume and distribution may require higher doses to achieve same effect, while decreased plasma protein binding may increase free fraction, potentiating effects. Alpha-1-acid glycoprotein levels change in pregnancy, affecting binding. In third trimester, clearance may be increased by up to 50% due to enhanced hepatic metabolism. Therefore, dose adjustments may be needed: consider starting at low dose and titrating to effect, with close monitoring. For intravenous administration, typical adult doses (5-20 μg/kg) may need adjustments; no standard pregnancy-specific dosing exists. Use the lowest effective dose for the shortest duration. In labor, avoid high doses prior to delivery due to risk of neonatal respiratory depression.
Diphenhydramine is a first-generation antihistamine with strong anticholinergic effects; avoid in elderly due to increased risk of confusion, falls, and urinary retention. Rapid IV administration can cause hypotension and arrhythmias; give slow IV push. Use with caution in patients with glaucoma, prostate hypertrophy, or asthma. Onset of sedation within 30-60 minutes; useful for acute dystonias (e.g., from antipsychotics) at 25-50 mg IM/IV. Not recommended for children <2 years due to risk of respiratory depression.
Alfentanil is a potent, rapid-onset, short-acting opioid analgesic used primarily for induction and maintenance of anesthesia. Due to its high protein binding (90%) and rapid redistribution, it has a shorter duration of action than fentanyl, making it suitable for brief, painful procedures. It undergoes hepatic metabolism via CYP3A4, so concomitant use with CYP3A4 inhibitors like ketoconazole or erythromycin can prolong its effects. Use caution in elderly or hypovolemic patients due to increased risk of hypotension. Naloxone reverses respiratory depression. Alfentanil is 5-10 times less potent than fentanyl.
Do not drive or operate heavy machinery until you know how this drug affects you, as it causes drowsiness.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they increase sedation and fall risk.,Dry mouth, blurred vision, and constipation are common; drink water and use sugar-free gum for dry mouth.,If you have difficulty urinating or eye pain, stop the medication and seek medical help.,Do not exceed recommended dose; overdose can cause seizures, hallucinations, or serious heart problems.,Take with food if stomach upset occurs, but avoid grapefruit juice as it may affect drug metabolism.
This medication is given only by a healthcare professional in a hospital or surgical setting.,You may feel drowsy, dizzy, or nauseated after receiving this drug.,Report any difficulty breathing or slow heart rate to your healthcare provider immediately.,Avoid alcohol and sedatives for 24 hours after administration, as they can increase side effects.,Do not drive or operate machinery until the effects have fully worn off.
"Diphenhydramine, a first-generation antihistamine with significant central nervous system (CNS) depressant effects, and clonazepam, a benzodiazepine that enhances GABA-A receptor activity, produce additive CNS depression when co-administered. This synergistic effect increases the risk of excessive sedation, psychomotor impairment, respiratory depression, and potential for falls, especially in elderly patients. Clinically, patients may experience profound drowsiness, confusion, ataxia, and impaired cognitive and motor function, which can lead to accidents or worsen sleep-disordered breathing."
"Concurrent use of diphenhydramine and butalbital results in additive central nervous system (CNS) depression due to their overlapping sedative-hypnotic properties. Diphenhydramine, a first-generation antihistamine, antagonizes histamine H1 receptors and crosses the blood-brain barrier, while butalbital, a barbiturate, enhances GABA-A receptor activity. This synergism can lead to excessive sedation, impaired cognitive and motor function, respiratory depression, and increased risk of accidental injury or overdose, particularly in elderly patients or those with hepatic impairment."
"Cevimeline, a muscarinic agonist used for xerostomia, can inhibit the metabolism of diphenhydramine by competitively blocking cytochrome P450 (CYP) 2D6 and 3A4 enzymes. This results in reduced clearance of diphenhydramine, leading to elevated plasma concentrations and increased risk of anticholinergic side effects such as sedation, confusion, dry mouth, blurred vision, and urinary retention. Clinically, patients may experience enhanced and prolonged central nervous system depression and anticholinergic toxicity."
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about Diphenhydramine vs ALFENTA, answered by our medical review team.
Diphenhydramine is a Antihistamine that works by Inverse agonist at histamine H1 receptors, blocking histamine-mediated effects in blood vessels, respiratory smooth muscle, and GI tract; also anticholinergic by blocking muscarinic receptors and sedative via central H1 receptor antagonism.. ALFENTA is a Opioid Analgesic that works by μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between Diphenhydramine and ALFENTA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of Diphenhydramine is: 25-50 mg orally or intramuscularly every 4-6 hours; maximum 300 mg/day. Intravenous administration: 10-50 mg slow IV push (max 25 mg/min).. The standard adult dose of ALFENTA is: Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining Diphenhydramine and ALFENTA. The combination of Alfentanil, an opioid analgesic, with Diphenhydramine, a first-generation antihistamine with sedative properties, results in additive central nervous system (CNS) depression. This can lead to increased sedation, respiratory depression, and potential for coma or death, especially in elderly or debilitated patients. Clinicians should be aware of the heightened risk of hypotension and bradycardia due to additive cardiovascular effects. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. Diphenhydramine is classified as Category C. First trimester: No increased risk of major congenital anomalies based on large cohort studies, though a weak association with oral clefts has been reported (RR ~1.3-1.5). Second t. ALFENTA is classified as Category C. Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effect. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.